PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'National Institute of Health and Research Development, Ministry of Health, Republic of Indonesia (NIHRD, MoH RI), Jakarta, Indonesia. mkaryana@ina-respond.net.\', \'RSUP Dr. Wahidin Sudirohusodo, Pulmonology and Respiratory Medicine, Medical Faculty, Hasanuddin University, Makassar, Indonesia.\', \'National Institute of Health and Research Development, Ministry of Health, Republic of Indonesia (NIHRD, MoH RI), Jakarta, Indonesia.\', \'RSUP Dr. Wahidin Sudirohusodo, Makassar, Indonesia.\', \'Daewoong Pharmaceutical Co Ltd., Seoul, Republic of Korea.\', \'Daewoong Infion, Jakarta, Indonesia.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s13287-022-02812-4
?:doi
?:hasPublicationType
?:journal
  • Stem cell research & therapy
is ?:pmid of
?:pmid
?:pmid
  • 35365239
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all